Aluminium chloride is a neurotoxin that has been linked to the cause of Alzheimer's disease (AD) for decades. In situ, long-term aluminium toxicity causes oxidative stress and raises amyloid beta levels. Treatment options for Alzheimer's disease now only include symptomatic relief, necessitating the creation of alternative medications with fewer side effects. The researchers wanted to see whether long-term administration of resveratrol coated with Selenium nanoparticles (RSV-Nanoselenium) could shield rats from aluminum-induced AD pathogenesis and oxidative injury. In this study male albino wistar rats were orallyadministered withaluminum chloride (300 mg/kg b.wt)once daily for 30 days for induction of AD. The rats of induced model of AD were orally administrated with RSV-Nanoselenium (200 mg/kg, b.wt)once daily for 3 weeks.The rats were scarified on the 52ndand brain tissue of each rat was dissected and frozen at −80 °C. Biochemical research was conducted to determine the degree of oxidative injurythrough measuring Catalase, Glutathione (GSH), Malondialdehyde (MDA), γ-Secretase and Calcium levels in brain tissue.Aluminium chloride administration caused neurotoxicity and severe memory loss, as well as significant oxidative harm. It also resulted in substantial rise in γ-secretase and a significant decrease in calcium levels. RSV-Nanoselenium administration increased neuronal transmission by reducing oxidative stress and metal chelation in AD model of rats (P< 0.05). RSV-Nanoselenium protects against AD and oxidative harm caused by aluminium.